In one paragraph
Tessera works on a different idea from most editing companies: rather than changing letters, insert whole working sequences using natural machinery that already moves DNA around. That would matter most for diseases where the gene is too large or the mutations too varied for letter-by-letter approaches.
Tessera Therapeutics, founded in 2018 by Flagship Pioneering, develops Gene Writing technology based on engineered retrotransposons and related mobile elements capable of inserting kilobase-scale sequence. Programmes span sickle cell disease, alpha-1 antitrypsin deficiency and phenylketonuria; the work remains preclinical.
Sources
- Tessera Therapeutics
Tessera Therapeutics ↗
Not investment advice
This profile is educational information compiled from public disclosures. It is not a recommendation to buy, sell or hold any security, and it is not a view on the company's prospects. Biotechnology is highly speculative and most clinical programmes fail.
Full disclaimers →